Publication - Research and analysis
2010/11 Scottish Crime and Justice Survey: Drug Use
This report presents findings from the Scottish Crime and Justice Survey 2010/11 Drug Use module. The report provides information on the experience and prevalence of illicit drug use amongst the general adult population in Scotland.
Table A1.4: % of adults aged 16 or over who reported having ever used illicit drugs by age group
Source: SCJS 2010/11. Variable name: QEVE.
| All ages % |
16-24 % |
25-44 % |
45-59 % |
60+ % |
|
|---|---|---|---|---|---|
| CLASS A | 11.7 | 19.0 | 21.0 | 7.9 | 0.7 |
| Cocaine | 7.1 | 12.9 | 13.1 | 3.8 | 0.1 |
| Crack | 0.8 | 1.5 | 1.4 | 0.3 | - |
| Ecstasy | 7.2 | 14.6 | 14.0 | 2.2 | 0.1 |
| Heroin | 0.8 | 0.7 | 1.6 | 0.7 | 0.1 |
| Methadone | 0.7 | 1.1 | 1.4 | 0.5 | * |
| LSD | 4.9 | 3.9 | 9.6 | 4.7 | 0.4 |
| Magic mushrooms | 5.2 | 5.4 | 9.5 | 4.9 | 0.4 |
| CLASS B | 22.2 | 35.3 | 36.3 | 17.9 | 3.1 |
| Amphetamines | 7.8 | 9.9 | 14.9 | 5.8 | 0.3 |
| Crystal Meth | 0.3 | 0.4 | 0.5 | 0.2 | 0.1 |
| Cannabis | 21.6 | 34.7 | 34.9 | 17.5 | 3.1 |
| CLASS C | 5.2 | 9.3 | 8.8 | 3.5 | 0.7 |
| Anabolic steroids | 0.3 | 0.6 | 0.5 | 0.3 | * |
| Ketamine | 1.2 | 3.4 | 2.0 | 0.3 | * |
| Temazepam | 2.0 | 2.1 | 4.1 | 1.6 | * |
| Valium | 3.9 | 7.1 | 6.6 | 2.5 | 0.6 |
| NOT CLASSIFIED | |||||
| Glues/solvents/gas/aerosols | 2.2 | 3.4 | 4.1 | 1.3 | 0.2 |
| Poppers | 6.4 | 13.1 | 11.6 | 3.0 | 0.2 |
| NEW DRUGS | 1.8 | 6.0 | 2.3 | 0.6 | 0.1 |
| BZP | 0.1 | 0.2 | 0.3 | 0.1 | - |
| GBL | 0.2 | 0.3 | 0.4 | 0.1 | - |
| Khat | 0.2 | 0.5 | 0.3 | 0.2 | 0.1 |
| Mephedrone | 1.2 | 5.5 | 1.2 | 0.1 | - |
| Synthetic cannabinoids | 0.4 | 1.2 | 0.7 | 0.2 | * |
| ANY STIMULANTS | 12.5 | 21.2 | 22.9 | 7.6 | 0.6 |
| ANY OPIATES | 1.0 | 1.4 | 1.8 | 0.9 | 0.1 |
| ANY PSYCHEDELICS | 7.5 | 9.0 | 13.6 | 6.5 | 0.6 |
| ANY DOWNERS / TRANQ. | 4.6 | 8.0 | 7.8 | 3.1 | 0.6 |
| ANY DRUGS | 23.7 | 37.2 | 38.2 | 19.7 | 3.8 |
| ANY DRUGS EXCLUDING NEW DRUGS | 23.7 | 37.2 | 38.1 | 19.5 | 3.7 |
| Base | 10,977 | 968 | 3,298 | 2,916 | 3,793 |
Contact
Email: Stuart King